Answers are grounded in this paper and cite their sources.
Demonstrates altered ligand specificity in NK cells, indicating potential immunotherapy implications.
The activating receptor NKp30 is important in NK cell killing of cancer cells. Here, we demonstrated that a pair of splice signals in the Ig domain exon of human NKp30 is largely conserved among primates and placental mammals and produces an alternatively spliced NKp30 ectodomain (NKp30‐S) with an in‐frame, nonartefactual deletion of 25 amino acid residues. Transfection yielded NKp30‐S bands in NKL cells but not in 293T cells, suggesting that the splicing mechanism is cell‐specific. Molecular modeling indicated that the overall folding of NKp30‐S is maintained compared with NKp30. NKp30‐S was expressed at the cell surface but did not bind to the NKp30 ligand B7H6 in soluble fusion protein or reporter cell assays. Single‐cell RNA sequencing showed that NKp30‐S transcription was not restricted to major NK cell subsets but suggested that a small fraction of blood NK cells expressed only the NKp30‐S splice variant. The ratio of NKp30‐S to full‐length transcript was increased after activation of blood NK cells with IL‐2 or IL‐15 or crosslinking with anti‐CD16 antibody, suggesting that this unique splicing mechanism, not seen in other Ig superfamily proteins, is regulated and may play a role in modulating NK cell responsiveness toward B7H6 + cancer cells in vivo.
No takes yet. Share an insight, caveat, or question.
Bjørnsen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: